Eric Escobar Cabrera

Title: Eric Escobar Cabrera: Innovator in Antibody Therapeutics

Introduction

Eric Escobar Cabrera is a prominent inventor based in Burnaby, Canada. He has made significant contributions to the field of antibody therapeutics, holding 2 patents that focus on innovative approaches to cancer and infectious disease treatment.

Latest Patents

Cabrera's latest patents include the development of anti-PD-1/LAG3 bispecific antibodies. These antibodies and their antigen-binding fragments are designed for use in treating cancer or infectious diseases. Another notable patent involves a stable heterodimeric antibody design with mutations in the Fc domain. This design features heavy chains that are asymmetric in various domains, allowing for selectivity between different Fc receptors. This innovation enhances the stability and purity of the resulting variant Fc heterodimers, which are crucial for therapeutic applications.

Career Highlights

Throughout his career, Cabrera has worked with leading companies in the biotechnology sector, including Zymeworks Inc. and Merck Sharp & Dohme Corporation. His work has been instrumental in advancing the understanding and application of antibody therapies.

Collaborations

Cabrera has collaborated with notable professionals in his field, including Thomas Spreter Von Kreudenstein and Surjit Bhimarao Dixit. These collaborations have further enriched his research and development efforts.

Conclusion

Eric Escobar Cabrera is a key figure in the development of innovative antibody therapies. His patents and collaborations reflect his commitment to advancing medical science and improving treatment options for patients.